secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001628280-25-049604
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Context Therapeutics Q3 net loss $9.7M; early clinical data for CTIM-76 and CT-95
--------------------------------------------------------------------------------

- Q3 net loss $9.7M, down from $17.5M YoY; cash $76.9M sufficient into 2027.
- CTIM-76 Phase 1: 12 patients; RECIST response observed from Cohort 3; no CRS>Grade1, no DLT.
- CT-95 Phase 1: 6 patients; approaching target dose with Cohort 4; no CRS>Grade2.
- CT-202 (Nectin-4 x CD3) preclinical; expects regulatory filing for first-in-human trial in Q2 2026.
- Anticipates updated CTIM-76 Phase 1a data and Phase 1b dose selection in Q2 2026; CT-95 data mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000162828025049604/0001628280-25-049604-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000162828025049604/cntx-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-049604

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer